Back to News
Market Impact: 0.22
Biohaven And SK Biopharmaceuticals Enter Strategic Global Licensing Agreement; Stock Up
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationCompany FundamentalsPatents & Intellectual Property
Biohaven (BHVN) and SK Biopharmaceuticals entered a global licensing and collaboration deal covering Biohaven’s Kv7 ion channel platform. The agreement centers on Opakalim (BHV-7000), Biohaven’s next-generation epilepsy candidate in development, which adds product development and commercialization momentum for the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BHVN0.45
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- AI's Supercharging a Scam Economy Bigger Than the Cocaine Trade
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies